Marc Iskowitz is the Executive Editor for MM+M, a publication focused on healthcare marketing and communications. With his work featured in Campaign US and PRWeek, Marc covers a wide range of topics in the pharmaceutical industry, including drug development, healthcare policy, and marketing trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Marc Iskowitz focuses on the healthcare and pharmaceutical industry, with a predominant emphasis on press releases and cited data. His articles cover various aspects such as drug launches, healthcare marketing, surveys, and drug pricing.
Given his focus on press releases and cited data, Marc would likely be interested in pitches that provide access to exclusive or significant data related to the pharmaceutical industry. Additionally, he may welcome expert insights into new drug launches or trends in healthcare marketing based on credible sources within the industry.
Although Marc's geographic focus is not specified, his coverage appears to have a broader international perspective. Therefore, relevant information from any location can potentially pique his interest if it aligns with his areas of coverage within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The announcement marks the conclusion of a process that began when Eversana acquired the Salerno-based shop last fall.
By: Marc Iskowitz
For decades April 20 has been a day to celebrate cannabis culture. But 4/20-related marketing may have become a victim of its own success.
The FTC crackdown comes six months after the regulator challenged drugmakers in a similar fashion.
Revenue climbed 16% to an MM+M-estimated $92.5 million.
Revenue climbed 5% to an MM+M-estimated $430 million.
By: Marc Iskowitz
For seasoned agency execs Walter Geer III and John Duffield, experience has proven the ultimate teacher.
Ads promoting Ro's two-in-one ED drug skirt multiple levels of drug-advertising oversight, medical marketing experts say.
By: Marc Iskowitz
The drugmaker’s outlay, more than three times larger than its next-closest pharma peer, coincided with Humira’s loss of patent protection.
By: Marc Iskowitz
The drugmaker's outlay, more than three times larger than its next-closest pharma peer, coincided with Humira's loss of patent protection.
By: Marc Iskowitz
In the first part of a three-part series, MM+M examines the factors underlying the need for regulatory guidance on combating the proliferation of online health misinformation.
(833) 317-6278 
